Logo

Factor Bioscience Collaborates with Eterna Therapeutics to Develop Cell Therapy Focusing on Oncology, Autoimmune and Rare Diseases

Share this

Factor Bioscience Collaborates with Eterna Therapeutics to Develop Cell Therapy Focusing on Oncology, Autoimmune and Rare Diseases

Shots:

  • Factor Bioscience & Eterna Therapeutics have entered into an exclusive license & collaboration agreement to expedite the development of cell therapies focusing on oncology, rare diseases & autoimmune disorders
  • As per the agreement, Eterna received an exclusive global non-transferable royalty-bearing license, with the right to grant sublicenses, for developing and commercializing iPSC-based cell therapies using Factor’s reprogramming & gene-editing technologies, patents & expertise
  • Both the companies will generate efficacy data of the candidates to proceed for IND by Eterna (or by third-party sublicensees), with Factor receiving milestones per candidate & royalties after marketing

Ref: Factor Bioscience | Image: Factor Bioscience and Eterna Therapeutics

Related News: Sanofi Collaborates with Orano Med for the Development of Next-Generation Radioligand Therapies

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions